Cohance Lifesciences Shares Price Drop Over 7% After Q2 Profit Falls 52%

Mumbai, November 13: Cohance Lifesciences Limited (INE03QK01018) reported a steep decline in its earnings for the quarter ended September 30, 2025. The company’s profit for Q2 FY26 fell 52% year-on-year, reflecting weak operational performance. The sharp drop in profitability triggered a sell-off, with the shares falling over 7% in early Thursday trading.

Q2 FY26 Consolidated Performance (YoY)

The company made Rs 555.6 crore in revenue from operations during the Q2 FY26. This was an 8% YoY decline from Rs 603.8 crore. The adjusted EBITDA also decreased from Rs 216.3 crore in Q2 FY25 to Rs 128.9 crore in Q2 FY26, marking a 40.4% YoY decline. The impact of the same was visible on profit after tax, which declined 52% YoY, dipping from Rs 138.2 crore in Q2 FY25 to Rs 66.4 crore in Q2 FY26.

Market Snapshot

The share price of Cohance Lifesciences Limited was trading at ₹636.95 as of November 13, 2025, 11:07 am. This was a 7.68% or ₹52.95 fall from its previous close of ₹689.90. The intraday range so far has been between ₹621.20 and ₹676.55. The company has had a negative trading session so far. Its total market capitalisation stood at ₹24,396.31 crore. Further, it had a total traded value and volume of ₹155.68 crore and 24.43 lakh shares, respectively.

Cohance Lifesciences Limited is a pharmaceutical company that manufactures and supplies products across various sectors. Listed on both the NSE and BSE since March 2020 under the tickers INE03QK01018 and 543064, respectively, the company is also a constituent of the Nifty Smallcap 250 index.

REF: https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_12112025185506_Cohance_Investor_Presentation_12112025.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations